Human immunodeficiency virus (HIV) latency: The major hurdle in HIV eradication

Molecular Medicine

Volumn 18, Issue 7, 2012, Pages 1096-1098

  Tyagi, Mudit ^a   Bukrinsky, Michael ^b  

^a GEORGE MASON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TRANSCRIPTION FACTOR;

ARTICLE; EPIGENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; TRANSCRIPTION REGULATION; TREATMENT PLANNING; VIREMIA; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; VIRUS INTERFERENCE; VIRUS LATENCY; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

DISEASE ERADICATION; HIV; HIV INFECTIONS; HUMANS; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES; VIRUS LATENCY;

EID: 84866753757     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00194     Document Type: Article

References (240)

1. Waxman MJ, et al. (2008) The role of emergency department HIV care in resource-poor settings: lessons learned in western Kenya. Int. J. Emerg. Med. 1:317-20.
2. Branson BM, et al. (2006) Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm. Rep. 55:1-17.
3. Jacobson LP, Phair JP, Yamashita TE. (2002) Virologic and immunologic response to highly active antiretroviral therapy. Curr. Infect. Dis. Rep. 4:88-96.
4. Egger M, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 360:119-29.
5. (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010 [PDF from Internet]. Geneva: World Health Organization; [cited 2012 Sep 14]. Available from: http://www.who. int/hiv/pub/2010progressreport/en/
6. Collman R, et al. (1989) Infection of monocytederived macrophages with human immunodeficiency virus type 1 (HIV-1): monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types. J. Exp. Med. 170:1149-63.
7. Orenstein JM, Fox C, Wahl SM. (1997) Macrophages as a source of HIV during opportunistic infections. Science. 276:1857-61.
8. Ho DD, Rota TR, Hirsch MS. (1986) Infection of monocyte/macrophages by human T lympho-tropic virus type III. J. Clin. Invest. 77:1712-5.
9. Nicholson JK, et al. (1986) In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). J. Immunol. 137:323-9.
10. Aquaro S, et al. (2002) Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res. 55:209-25.
11. Perno CF, et al. (1998) Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J. Infect. Dis. 178:413-22.
12. Richman DD, et al. (2009) The challenge of finding a cure for HIV infection. Science. 323:1304-7.
13. Finzi D, et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-7.
14. Chun T-W, et al. (1998) Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 95:8869-73.
15. Chun TW, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 387:183-8.
16. Chun TW, et al. (1998) Induction of HIV-1 replication in latently infected CD4+ cells using a combination of cytokines. J. Exp. Med. 188:83-91.
17. Finzi D, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1295-300.
18. Persaud D, et al. (2000) A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J. Clin. Invest. 105:995-1003.
19. Siliciano JD, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727-8.
20. Chun TW, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 94:13193-7.
21. Siliciano RF, Greene WC. (2011) HIV latency. Cold Spring Harb. Perspect. Med. 1:a007096.
22. Choudhary SK, Margolis DM. (2011) Curing HIV: pharmacologic approaches to target HIV-1 latency. Annu. Rev. Pharmacol. Toxicol. 51:397-418.
23. Karn J. (2011) The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr. Opin. HIV AIDS. 6:4-11.
24. Chun TW, et al. (1999) Re-emergence of HIV after stopping therapy. Nature. 401:874-5.
25. Davey RT Jr, et al. (1999) HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. U. S. A. 96:15109-14.
26. Friis-Moller N, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349:1993-2003.
27. Friis-Moller N, et al. (2003) Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy: results from the DAD study. AIDS. 17:1179-93.
28. Deeks SG, Phillips AN. (2009) HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 338:a3172.
29. Valcour V, et al. (2011) The effects of age and HIV on neuropsychological performance. J. Int. Neuropsychol. Soc. 17:190-5.
30. Neuhaus J, et al. (2010) Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS. 24:697-706.
31. Perrin L, Kaiser L, Yerly S. (2003) Travel and the spread of HIV-1 genetic variants. Lancet Infect. Dis. 3:22-7.
32. Bongaarts J, Over M. (2010) Public health: global HIV/AIDS policy in transition. Science. 328:1359-60.
33. Salit IE, et al. (2005) Travel patterns and risk behaviour of HIV-positive people travelling internationally. CMAJ. 172:884-8.
34. Orisatoki RO, Oguntibeju OO, Truter EJ. (2009) The contributing role of tourism in the HIV/AIDS epidemic in the Caribbean. Niger. J. Med. 18:143-8.
35. Ross EK, et al. (1991) Contribution of NF-kB and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. J. Virol. 65:4350-8.
36. Jones K, et al. (1986) Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science. 232:755-9.
37. Olsen HS, Rosen CA. (1992) Contribution of the TATA motif to Tat-mediated transcriptional activation of the human immunodeficiency virus gene expression. J. Virol. 66:5594-7.
38. Rittner K, et al. (1995) The human immunodeficiency virus long terminal repeat includes a specialised initiator element which is required for Tatresponsive transcription. J. Mol. Biol. 248:562-80.
39. Garcia JA, et al. (1989) Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J. 8:765-78.
40. Nabel G, Baltimore DA. (1987) An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 326:711-3.
41. Kinoshita S, et al. (1997) The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity. 6:235-44.
42. Perkins ND, et al. (1993) A cooperative interaction between NF-kB and Sp1 is required for HIV-1 enhancer activation. EMBO J. 12:3551-8.
43. Gerritsen ME, et al. (1997) CREB-binding protein/p300 are transcriptional coactivators of p65. Proc. Natl. Acad. Sci. U. S. A. 94:2927-32.
44. Garcia-Rodriguez C, Rao A. (1998) Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREBbinding protein (CBP). J. Exp. Med. 187:2031-6.
45. Alcami J, et al. (1995) Absolute dependence on kB responsive elements for initiation and Tatmediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J. 14:1552-60.
46. Bosque A, Planelles V. (2009) Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood. 113:58-65.
47. Pearson R, et al. (2008) Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J. Virol. 82:12291-303.
48. Chen BK, Feinberg MB, Baltimore D. (1997) The kB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth. J. Virol. 71:5495-504.
49. Nechaev S, Adelman K. (2011) Pol II waiting in the starting gates: regulating the transition from transcription initiation into productive elongation. Biochimica Biophysica Acta. 1809:34-45.
50. Cho S, Schroeder S, Ott M. (2010) CYCLINg through transcription posttranslational modifications of P-TEFb regulate transcription elongation. Cell Cycle. 9:1697-705.
51. Karn J. (1999) Tackling Tat. J. Mol. Biol. 293:235-54.
52. Taube R, et al. (1999) Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation. Virology. 264:245-53.
53. Wei P, et al. (1998) A novel cdk9-associated c-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop specific binding to TAR RNA. Cell. 92:451-62.
54. Herrmann CH, Rice AP. (1995) Lentivirus Tat proteins specifically associate with a cellular protein-kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 69:1612-20.
55. Parada CA, Roeder RG. (1996) Enhanced processivity of RNA polymerase II triggered by Tatinduced phosphorylation of its carboxy-terminal domain. Nature. 384:375-8.
56. Kim YK, et al. (2002) Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol. Cell. Biol. 22:4622-37.
57. Bourgeois CF, et al. (2002) Spt5 cooperates with Tat by preventing premature RNA release at terminator sequences. Mol. Cell. Biol. 22:1079-93.
58. Fujinaga K, et al. (2004) Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol. Cell. Biol. 24:787-95.
59. Ivanov D, et al. (2000) Domains in the SPT5 protein that modulate its transcriptional regulatory properties. Mol. Cell. Biol. 20:2970-83.
60. Liou LY, Herrmann CH, Rice AP. (2002) Transient induction of cyclin T1 during human macrophage differentiation regulates human immunodeficiency virus type 1 Tat transactivation function. J. Virol. 76:10579-87.
61. Peterlin BM, Price DH. (2006) Controlling the elongation phase of transcription with P-TEFb. Mol. Cell. 23:297-305.
62. Tyagi M, Pearson RJ, Karn J. (2010) Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 84:6425-37.
63. Colin L, Van Lint C. (2009) Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology. 6:111.
64. Weinberger LS, et al. (2005) Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell. 122:169-82.
65. Weinberger LS, Dar RD, Simpson ML. (2008) Transient-mediated fate determination in a transcriptional circuit of HIV. Nat. Genet. 40:466-70.
66. Burnett JC, et al. (2009) Control of stochastic gene expression by host factors at the HIV promoter. PLoS Pathog. 5:e1000260.
67. Tyagi M, Romerio F. (2011) Models of HIV-1 Persistence in the CD4+ T Cell compartment: past, present and future. Curr. HIV Res. 9:579-87.
68. Ott M, Geyer M, Zhou Q. (2011) The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe. 10:426-35.
69. Mbonye U, Karn J. (2011) Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr. HIV Res. 9:554-67.
70. Wolffe AP. (1994) Nucleosome positioning and modification: chromatin structures that potentiate transcription. Trends Biochem. Sci. 19:240-4.
71. Narlikar GJ, Fan HY, Kingston RE. (2002) Cooper ation between complexes that regulate chromatin structure and transcription. Cell. 108:475-87.
72. Felsenfeld G, Groudine M. (2003) Controlling the double helix. Nature. 421:448-53.
73. Kouzarides T. (2007) Chromatin modifications and their function. Cell. 128:693-705.
74. Verdin E. (1991) DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhances of integrated human immunodeficiency virus type 1. J. Virol. 65:6790-9.
75. Verdin E, Paras PJ, Van Lint C. (1993) Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J. 12:3249-59.
76. Jordan A, Defechereux P, Verdin E. (2001) The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 20:1726-38.
77. Jordan A, Bisgrove D, Verdin E. (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22:1868-77.
78. Kauder SE, et al. (2009) Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 5:e1000495.
79. Blazkova J, et al. (2009) CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 5:e1000554.
80. Chavez L, Kauder S, Verdin E. (2011) In vivo, in vitro, and in silico analysis of methylation of the HIV-1 provirus. Methods. 53:47-53.
81. Tyagi M, Karn J. (2007) CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 26:4985-95.
82. Coull JJ, et al. (2000) The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J. Virol. 74:6790-9.
83. Hsia SC, Shi YB. (2002) Chromatin disruption and histone acetylation in regulation of the human immunodeficiency virus type 1 long terminal repeat by thyroid hormone receptor. Mol. Cell. Biol. 22:4043-52.
84. Williams SA, et al. (2006) NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25:139-49.
85. Marban C, et al. (2007) Recruitment of chromatinmodifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J. 26:412-23.
86. Imai K, Okamoto T. (2006) Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J. Biol. Chem. 281:12495-505.
87. Friedman J, et al. (2011) Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J. Virol. 85:9078-89.
88. Enderle D, et al. (2011) Polycomb preferentially targets stalled promoters of coding and noncoding transcripts. Genome Res. 21:216-26.
89. Margolis DM. (2011) Histone deacetylase inhibitors and HIV latency. Curr. Opin. HIV AIDS. 6:25-9.
90. Hakre S, et al. (2011) Epigenetic regulation of HIV latency. Curr. Opin. HIV AIDS. 6:19-24.
91. Bowman MC, Archin NM, Margolis DM. (2009) Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev. Mol. Med. 11:e6.
92. Savarino A, et al. (2009) "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology. 6:52.
93. Hargreaves DC, Crabtree GR. (2011) ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res. 21:396-420.
94. Liu N, Balliano A, Hayes JJ. (2011) Mechanism(s) of SWI/SNF-induced nucleosome mobilization. Chembiochem. 12:196-204.
95. Rafati H, et al. (2011) Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. PLoS Biol. 9:e1001206.
96. Agbottah E, et al. (2006) Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. Retrovirology. 3:48.
97. Van Duyne R, et al. (2011) Varying modulation of HIV-1 LTR activity by Baf complexes. J. Mol. Biol. 411:581-96.
98. Mahmoudi T, et al. (2006) The SWI/SNF chromatin-remodeling complex is a cofactor for tat transactivation of the HIV promoter. J. Biol. Chem. 281:19960-8.
99. Henderson A, et al. (2004) Recruitment of SWI/SNF to the human immunodeficiency virus type 1 promoter. Mol. Cell. Biol. 24:389-97.
100. Treand C, et al. (2006) Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J. 25:1690-9.
101. Schroder AR, et al. (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 110:521-9.
102. Han Y, et al. (2004) Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78:6122-33.
103. Meehan AM, et al. (2009) LEDGF/p75 proteins with alternative chromatin tethers are functional HIV-1 cofactors. PLoS Pathog. 5:e1000522.
104. Lewinski MK, et al. (2006) Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog. 2:e60.
105. Vatakis DN, et al. (2009) Human immunodeficiency virus integration efficiency and site selection in quiescent CD4(+) T cells. J. Virol. 83:6222-33.
106. Brady T, et al. (2009) HIV integration site distributions in resting and activated CD4(+) T cells infected in culture. AIDS. 23:1461-71.
107. Han Y, et al. (2008) Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe. 4:134-46.
108. Lenasi T, Contreras X, Peterlin BM. (2008) Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe. 4:123-33.
109. De Marco A, et al. (2008) Intragenic transcriptional cis-activation of the human immunodeficiency virus 1 does not result in allele-specific inhibition of the endogenous gene. Retrovirology. 5:98.
110. Pomerantz RJ, et al. (1991) The long terminal repeat is not a major determinant of the cellular tropism of human immunodeficiency virus type 1. J. Virol. 65:1041-5.
111. Lassen KG, et al. (2006) Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog. 2:e68.
112. Huang J, et al. (2007) Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat. Med. 13:1241-7.
113. Yeung ML, Benkirane M, Jeang KT. (2007) Small non-coding RNAs, mammalian cells, and viruses: regulatory interactions? Retrovirology. 4:74.
114. Bennasser Y, Yeung ML, Jeang KT. (2007) RNAi therapy for HIV infection: principles and practicalities. Biodrugs. 21:17-22.
115. Triboulet R, Benkirane M. (2007) Interplay between HIV-1 replication and the microRNAsilencing pathway. Medecine Sciences. 23:590-2.
116. Sun GH, Rossi JJ. (2011) MicroRNAs and their potential involvement in HIV infection. Trends Pharmacol. Sci. 32:675-81.
117. Kumar A, Jeang KT. (2008) Insights into cellular microRNAs and human immunodeficiency virus type 1 (HIV-1). J. Cell. Physiol. 216:327-31.
118. Huang J, et al. (2007) Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat. Med. 13:1241-7.
119. Sung TL, Rice AP. (2009) miR-198 inhibits HIV-1 gene expression and replication in monocytes and its mechanism of action appears to involve repression of cyclin T1. PLoS Pathog. 5:e1000263.
120. Corbeau P. (2008) Interfering RNA and HIV: reciprocal interferences. PLoS Pathog. 4:e1000162.
121. Narayanan A, et al. (2011) Analysis of the roles of HIV-derived microRNAs. Expert Opin. Biol. Ther. 11:17-29.
122. Klase Z, et al. (2007) HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol. Biol. 8:63.
123. Bohnlein E, et al. (1988) The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV. Cell. 53:827-36.
124. Duh EJ, et al. (1989) Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc. Natl. Acad. Sci. U. S. A. 86:5974-8.
125. Ganesh L, et al. (2003) The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature. 426:853-7.
126. West MJ, Lowe AD, Karn J. (2001) Activation of human immunodeficiency virus transcription in T cells revisited: NF-kappaB p65 stimulates transcriptional elongation. J. Virol. 75:8524-37.
127. Shan L, et al. (2011) Influence of host gene tran scription level and orientation on HIV-1 latency in a primary-cell model. J. Virol. 85:5384-93.
128. Cujec TP, et al. (1997) The HIV trans-activator Tat binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terinal domain of RNA polymerase II. Genes Dev. 11:2645-57.
129. Herrmann CH, Rice AP. (1995) Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 69:1612-20.
130. Jones KA, Peterlin BM. (1994) Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:717-43.
131. Selby MJ, Peterlin BM. (1990) Trans-activation by HIV-1 Tat via a heterologous RNA binding protein. Cell. 62:769-76.
132. Lassen K, et al. (2004) The multifactorial nature of HIV-1 latency. Trends Mol. Med. 10:525-31.
133. Chomont N, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15:893-900.
134. Chun TW, et al. (1995) In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1:1284-90.
135. Yang HC. (2011) Primary cell models of HIV latency. Curr. Opin. HIV AIDS. 6:62-7.
136. Blanpain C, et al. (2002) CCR5 and HIV infection. Receptors Channels. 8:19-31.
137. Ebert LM, McColl SR. (2002) Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4+ T lymphocytes. J. Immunol. 168:65-72.
138. Cayota A, et al. (1990) Preferential replication of HIV-1 in memory CD4+ subpopulation. Lancet. 336:941.
139. Zack JA, et al. (1990) HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 61:213-22.
140. Bukrinsky MI, et al. (1991) Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science. 254:423-7.
141. Zhou Y, et al. (2005) Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J. Virol. 79:2199-210.
142. Meyerhans A, et al. (1994) Restriction and enhancement of human-immunodeficiency-virus type-1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J. Virol. 68:535-40.
143. Pierson T, McArthur J, Siliciano RF. (2000) Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 18:665-708.
144. Saleh S, et al. (2007) CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood. 110:4161-4.
145. Smith MZ, Wightman F, Lewin SR. (2012) HIV reservoirs and strategies for eradication. Curr. HIV/AIDS Rep. 9:5-15.
146. Lin YL, et al. (2005) G-protein signaling triggered by R5 human immunodeficiency virus type 1 increases virus replication efficiency in primary T lymphocytes. J. Virol. 79:7938-41.
147. Wu YT, Yoder A. (2009) Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog. 5:e1000520.
148. Unutmaz D, et al. (1999) Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189:1735-46.
149. Wightman F, et al. (2010) Both CD31(+) and CD31 naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J. Infect. Dis. 202:1738-48.
150. Carter CC, et al. (2010) HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat. Med. 16:446-51.
151. Brooks DG, et al. (2001) Generation of HIV latency during thymopoiesis. Nat. Med. 7:459-64.
152. Deichmann M, Kronenwett R, Haas R. (1997) Expression of the human immunodeficiency virus type-1 coreceptors CXCR-4 (fusin, LESTR) and CKR-5 in CD34+ hematopoietic progenitor cells. Blood. 89:3522-8.
153. Aiuti A, et al. (1999) Human CD34(+) cells express CXCR4 and its ligand stromal cell-derived factor-1: implications for infection by T-cell tropic human immunodeficiency virus. Blood. 94:62-73.
154. Durand CM, et al. (2012) HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. J. Infect. Dis. 205:1014-8.
155. Yuan J, Crittenden RB, Bender TP. (2010) c-Myb promotes the survival of CD4(+)CD8(+) doublepositive thymocytes through upregulation of Bcl-xL. J. Immunol. 184:2793-804.
156. Gartner S, et al. (1986) The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 233:215-9.
157. Igarashi T, et al. (2001) Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc. Natl. Acad. Sci. U. S. A. 98:658-63.
158. Ho DD, Rota TR, Hirsch MS. (1986) Infection of monocyte/macrophages by human T-lymphotropic virus type III. J. Clin. Invest. 77:1712-5.
159. Le Douce V, et al. (2010) Molecular mechanisms of HIV-1 persistence in the monocytemacrophage lineage. Retrovirology. 7:32.
160. Pinti M, et al. (2003) Different sensitivity to apoptosis in cells of monocytic or lymphocytic origin chronically infected with human immunodeficiency virus type-1. Exp. Biol. Med. (Maywood). 228:1346-54.
161. Giri MS, et al. (2009) Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus-and hostmediated apoptosis resistance. J. Immunol. 182:4459-70.
162. Gras G, Kaul M. (2010) Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology. 7:30.
163. Schnell G, et al. (2010) Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J. Virol. 84:2395-407.
164. McArthur JC, et al. (2010) Human immunodeficiency virus-associated neurocognitive disorders mind the gap. Ann. Neurol. 67:699-714.
165. Churchill MJ, et al. (2009) Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann. Neurol. 66:253-8.
166. Gorry PR, et al. (1999) Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Tat and Rev. J. Virol. 73:352-61.
167. Davis LE, et al. (1992) Early viral brain invasion in iatrogenic human-immunodeficiency-virus infection. Neurology. 42:1736-9.
168. Lambotte O, et al. (2005) Persistence of replication-competent HIV in the central nervous system despite long-term effective highly active antiretroviral therapy. AIDS. 19:217-8.
169. Nath A, et al. (2008) Evolution of HIV dementia with HIV infection. Int. Rev. Psychiatry. 20:25-31.
170. Solas C, et al. (2003) Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47:238-43.
171. Aquaro S, et al. (2002) Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res, 55:209-25.
172. Yilmaz A, et al. (2010) Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 55:590-6.
173. Chun TW, et al. (2008) Persistence of HIV in gut-associated lymphoid tissue despite longterm antiretroviral therapy. J. Infect. Dis. 197:714-20.
174. Yukl SA, et al. (2010) Differences in HIV burden and immune activation within the gut of HIVpositive patients receiving suppressive antiretroviral therapy. J. Infect. Dis. 202:1553-61.
175. Guadalupe M, et al. (2006) Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J. Virol. 80:8236-47.
176. Dinoso JB, et al. (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 106:9403-8.
177. Dinoso JB, et al. (2009) A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J. Virol. 83:9247-57.
178. Besson GJ, et al. (2012) Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin. Infect. Dis. 54:451-3.
179. McMahon D, et al. (2010) Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin. Infect. Dis. 50:912-9.
180. Gandhi RT, et al. (2010) No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J. Infect. Dis. 201:293-6.
181. Gandhi RT, et al. (2012) No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 59:229-35.
182. Gandhi RT, et al. (2010) The effect of raltegravir intensification on low-level residual viremia in HIVinfected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 7:e1000321.
183. Hermankova M, et al. (2001) HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA. 286:196-207.
184. Imamichi H, et al. (2001) Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J. Infect. Dis. 183:36-50.
185. Joos B, et al. (2008) HIV rebounds from latently infected cells, rather than from continuing lowlevel replication. Proc. Natl. Acad. Sci. U. S. A. 105:16725-30.
186. Brennan TP, et al. (2009) Analysis of HIV-1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J. Virol. 83: 8470-81.
187. Tobin NH, et al. (2005) Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J. Virol. 79:9625-34.
188. Bailey JR, et al. (2006) Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80:6441-57.
189. Sahu GK, et al. (2009) Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J. Med. Virol. 81:9-15.
190. Nickle DC, et al. (2003) Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J. Virol. 77:5540-6.
191. Ruff CT, et al. (2002) Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J. Virol. 76:9481-92.
192. Sharova N, et al. (2005) Macrophages archive HIV-1 virions for dissemination in trans. EMBO J. 24:2481-9.
193. Swingler S, et al. (2007) Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog. 3:1281-90.
194. Rong L, Perelson AS. (2009) Modeling HIV persistence, the latent reservoir, and viral blips. J. Theor. Biol. 260:308-31.
195. Noe A, Plum J, Verhofstede C. (2005) The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J. Antimicrob. Chemother. 55:410-2.
196. Reece J, et al. (2012) An "escape clock" for estimating the turnover of SIV DNA in resting CD4+ T cells. PLoS Pathog. 8:e1002615.
197. Sallusto F, Geginat J, Lanzavecchia A. (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22:745-63.
198. Sallusto F, et al. (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:708-12.
199. Sereti I, et al. (2009) IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood. 113:6304-14.
200. Levy Y, et al. (2009) Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest. 119:997-1007.
201. Brooks DG, Zack JA. (2002) Effect of latent human immunodeficiency virus infection on cell surface phenotype. J. Virol. 76:1673-81.
202. Kutsch O, et al. (2002) Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J. Virol. 76:8776-86.
203. Folks TM, et al. (1989) Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl. Acad. Sci. U. S. A. 86:2365-8.
204. Folks TM, et al. (1987) Cytokine-induced expression of HIV-1 in a chronically infected pro-mono cyte cell line. Science. 238:800-2.
205. Folks T, et al. (1986) Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science. 231:600-2.
206. Burke B, et al. (2007) Primary cell model for activation-inducible human immunodeficiency virus. J. Virol. 81:7424-34.
207. Marini A, Harper JM, Romerio F. (2008) An in vitro system to model the establishment and reactivation of HIV-1 latency. J. Immunol. 181:7713-20.
208. Sahu GK, et al. (2006) A novel in vitro system to generate and study latently HIV-infected longlived normal CD4+ T-lymphocytes. Virology. 355:127-37.
209. Burnett JC, et al. (2010) Combinatorial latency reactivation for HIV-1 subtypes and variants. J. Virol. 84:5958-74.
210. Gondois-Rey F, et al. (2001) Production of HIV-1 by resting memory T lymphocytes. AIDS. 15:1931-40.
211. Swiggard WJ, et al. (2005) Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J. Virol. 79:14179-88.
212. Carter CC, et al. (2010) HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat. Med. 16:446-51.
213. Kauder SE, et al. (2009) Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 5:e1000495.
214. Yu D, et al. (2009) The HIV envelope but not VSV glycoprotein is capable of mediating HIV latent infection of resting CD4 T cells. PLoS Pathog. 5:e1000633.
215. Yang HC, et al. (2009) Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. Proc. Natl. Acad. Sci. U. S. A. 106:6321-6.
216. Yang HC, et al. (2009) Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 119:3473-86.
217. Xing S, et al. (2011) Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J. Virol. 85:6060-4.
218. Bosque A, et al. (2011) Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+T cells. PLoS Pathog. 7:e1002288.
219. Hakre S, et al. (2012) HIV latency: experimental systems and molecular models. FEMS Microbiol. Rev. 36:706-16.
220. Ramratnam B, et al. (2000) The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 6:82-5.
221. Chun TW, et al. (2005) HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115:3250-5.
222. Trono D, et al. (2010) HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 329:174-80.
223. Brooks DG, et al. (2003) Molecular characterization, reactivation, and depletion of latent HIV. Immunity. 19:413-23.
224. Archin NM, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses. 25:207-12.
225. Archin NM, et al. (2009) Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS. 23:1799-806.
226. Korin YD, et al. (2002) Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol. 76:8118-23.
227. Scripture-Adams DD, et al. (2002) Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J. Virol. 76:13077-82.
228. Kulkosky J, et al. (2001) Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood. 98:3006-15.
229. Ylisastigui L, et al. (2004) Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS. 18:1101-8.
230. Lehrman G, et al. (2005) Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 366:549-55.
231. Palmer S, Josefsson L, Coffin JM. (2011) HIV reservoirs and the possibility of a cure for HIV infection. J. Intern. Med. 270:550-60.
232. Shan L, et al. (2012) Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 36:491-501.
233. Vassena L, et al. (2012) Treatment with IL-7 prevents the decline of circulating CD4(+) T cells during the acute phase of SIV infection in Rhesus macaques. PLoS Pathog. 8:e1002636.
234. Hutter G, et al. (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360:692-8.
235. Allers K, et al. (2011) Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood. 117:2791-9.
236. DiGiusto DL, et al. (2010) RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2:36ra43.
237. Holt N, et al. (2010) Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28:839-47.
238. Perez EE, et al. (2008) Establishment of HIV-1 resistance in CD4(+) T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26:808-16.
239. Wilen CB, et al. (2011) Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zincfinger nucleases. PLoS Pathog. 7:e1002020.
240. Ho DD, Moudgil T, Alam M. (1989) Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N. Engl. J. Med. 321:1621-5.